JGUA
HAE icon

John G. Ullman & Associates’s Haemonetics HAE Stock Holding History

John G. Ullman & Associates’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$637K Sell
11,300
-2,300
-17% -$150K 0.08% 122
2025
Q4 		$1.09M Buy
13,600
+1,650
+14% +$111K 0.15% 99
2025
Q3 		$582K Buy
+11,950
New +$740K 0.08% 121

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

John G. Ullman & Associates's HAE Position: Q1 2026 in Review

John G. Ullman & Associates reduced its Haemonetics (HAE) stake by 17% in Q1 2026, selling an estimated $150K and leaving 11,300 shares worth $637K. The position accounts for 0.08% of the portfolio, ranked #122.

John G. Ullman & Associates first reported a position in HAE in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.09M in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • John G. Ullman & Associates held 11,300 shares of Haemonetics worth $637K as of Q1 2026.
  • John G. Ullman & Associates sold 2,300 Haemonetics shares in Q1 2026, an estimated $150K.
  • Haemonetics made up 0.08% of John G. Ullman & Associates's portfolio in Q1 2026, its #122 holding.
  • John G. Ullman & Associates first reported a position in Haemonetics in Q3 2025 and has held it in 3 quarters since.
  • John G. Ullman & Associates's Haemonetics position peaked at $1.09M in Q4 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.